Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 5;2(4):e373-e386.
doi: 10.1055/s-0038-1675577. eCollection 2018 Oct.

Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary (SEMI-SEOM-SETH) Expert Consensus

Affiliations

Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary (SEMI-SEOM-SETH) Expert Consensus

Vanessa Pachón et al. TH Open. .

Abstract

Despite the growing interest and improved knowledge about venous thromboembolism in cancer patients in the last years, there are still many unsolved issues. Due to the limitations of the available literature, evidence-based clinical practice guidelines are not able to give solid recommendations for challenging scenarios often present in the setting of cancer-associated thrombosis (CAT). A multidisciplinary expert panel from three scientific societies-Spanish Society of Internal Medicine (SEMI), Spanish Society of Medical Oncology (SEOM), and Spanish Society Thrombosis and Haemostasis (SETH)-agreed on 12 controversial questions regarding prevention and management of CAT, which were thoroughly reviewed to provide further guidance. The suggestions presented herein may facilitate clinical decisions in specific complex circumstances, until these can be made leaning on reliable scientific evidence.

Keywords: cancer; prophylaxis; pulmonary embolism; treatment; venous thrombosis.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest V.P. Advisory board: Daiichi-Sankyo.

E.G. Speaker honoraria: Rovi and Leo Pharma; advisory board: Sanofi, Leo Pharma, and Daiichi-Sankyo.

A.M. Speaker honoraria: Rovi; advisory board: Sanofi, Leo Pharma, and Daiichi-Sankyo.

R.L. Speaker honoraria: Rovi and Boehringer-Ingelheim; advisory board: Sanofi, Leo Pharma, and BMS. Research grant: Rovi.

All other authors declare no relevant conflict of interest associated with this work.

Similar articles

Cited by

References

    1. Lyman G H, Khorana A A, Kuderer N M et al.Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189–2204. - PubMed
    1. Guyatt G H, Akl E A, Crowther M, Gutterman D D, Schuünemann H J; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel.Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 2012141(2, Suppl):7S–47S. - PMC - PubMed
    1. Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines Ann Oncol 20112206vi85–vi92. - PubMed
    1. Farge D, Debourdeau P, Beckers M et al.International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11(01):56–70. - PubMed
    1. Muñoz A J, Viñolas N, Cubedo R, Isla D. SEOM guidelines on thrombosis in cancer patients. Clin Transl Oncol. 2011;13(08):592–596. - PubMed